Paul BA - CSL CEO MD
| CMXHF Stock | USD 154.28 3.76 2.38% |
Insider
Paul BA is CEO MD of CSL Limited
| Age | 66 |
| Phone | 61 3 9389 1911 |
| Web | https://www.csl.com.au |
CSL Management Efficiency
The company has return on total asset (ROA) of 0.0798 % which means that it generated a profit of $0.0798 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1964 %, meaning that it generated $0.1964 on every $100 dollars invested by stockholders. CSL's management efficiency ratios could be used to measure how well CSL manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Margaret Beaudoin | Verve Therapeutics | 55 | |
| MBA MBA | Alnylam Pharmaceuticals | 59 | |
| Deepika PharmD | Pmv Pharmaceuticals | 49 | |
| Prof MD | Ventyx Biosciences | N/A | |
| Lars Jorgensen | Novo Nordisk AS | 57 | |
| Birgitte MD | Ascendis Pharma AS | 62 | |
| Michael LLM | Ascendis Pharma AS | 54 | |
| Leila MD | Pmv Pharmaceuticals | 61 | |
| Thomas Shenk | Pmv Pharmaceuticals | 77 | |
| Harald MD | Zai Lab | 72 | |
| John MBA | Beam Therapeutics | 47 | |
| John McKune | Kalvista Pharmaceuticals | 48 | |
| Darin Weber | ProKidney Corp | 57 | |
| Feng Zhang | Beam Therapeutics | N/A | |
| Alfred Boyle | Alnylam Pharmaceuticals | N/A | |
| Timothy Lee | Ascendis Pharma AS | N/A | |
| Feng Zhang | Editas Medicine | N/A | |
| Brian Riley | Beam Therapeutics | 48 | |
| Deepak Jain | ProKidney Corp | 70 | |
| Suzanne Fleming | Beam Therapeutics | 63 | |
| MS BA | CSL | 53 | |
Management Performance
| Return On Equity | 0.2 | |||
| Return On Asset | 0.0798 |
CSL Limited Leadership Team
Elected by the shareholders, the CSL's board of directors comprises two types of representatives: CSL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CSL. The board's role is to monitor CSL's management team and ensure that shareholders' interests are well served. CSL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CSL's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul McKenzie, Chief Officer | ||
| BCom BComm, Chief Officer | ||
| Wilfried Freudenberg, Department Production | ||
| Christina Hickie, Sr Communications | ||
| BS BS, Exec Counsel | ||
| MS BA, Ex Officer | ||
| Karen Etchberger, Executive VP of Quality and Bus. Services | ||
| Paul BA, CEO MD | ||
| Jemimah Brennan, Head Pacific | ||
| Mark Dehring, Director of Investor Relations, IR Contact Officer |
CSL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CSL a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.0798 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 96.65 B | |||
| Shares Outstanding | 482.22 M | |||
| Shares Owned By Insiders | 0.41 % | |||
| Shares Owned By Institutions | 35.50 % | |||
| Price To Earning | 33.44 X | |||
| Price To Book | 6.65 X |
Currently Active Assets on Macroaxis
Other Information on Investing in CSL Pink Sheet
CSL financial ratios help investors to determine whether CSL Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CSL with respect to the benefits of owning CSL security.